Pancreatic Cancer Research

ResearcherUniversity of CologneActive in the last 2 years

Felix Popp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1690-6777; OpenAlex author ID A5022678280. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2017: 3 papers · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 17

  1. Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies. Co-author DOI 10.1038/s41420-026-02948-9↗
  2. MTAP-Deficiency Identifies a Myofibroblastic and Immune-Attenuated Tumor Microenvironment Subtype in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10656530/v1↗
  3. Tertiary Lymphoid Structures in Pancreatic Cancer are Structurally Homologous, Share Gene Expression Patterns and B-cell Clones with Secondary Lymphoid Organs,… Co-author DOI 10.1158/2326-6066.cir-24-0299↗
  4. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  5. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Co-author DOI 10.1016/j.tranon.2024.102044↗
  6. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  7. Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15072049↗
  8. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112689↗
  9. IL-17B/RB Activation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Metabolism and Growth. Last author DOI 10.3390/cancers13215338↗
  10. The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer. Last author DOI 10.3390/ijms21062215↗
  11. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Co-author DOI 10.7150/thno.43093↗
  12. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". Last author DOI 10.1186/s12885-019-6448-9↗
  13. Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. Co-author DOI 10.3390/cancers11060874↗
  14. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.32899↗
  15. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-017-2351-4↗
  16. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Co-author DOI 10.1155/2017/6012810↗
  17. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pan… Co-author DOI 10.1186/s12885-017-3186-8↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christiane J. Bruns · 17 shared papers, 2017–2026 · strength 2.36
  2. Yue Zhao · 13 shared papers, 2017–2026 · strength 1.59
  3. Alexander Quaas · 9 shared papers, 2019–2026 · strength 1.48
  4. Su Ir Lyu · 5 shared papers, 2023–2026 · strength 0.97
  5. Karl Knipper · 5 shared papers, 2023–2026 · strength 0.97
  6. Alexander Ioannis Damanakis · 6 shared papers, 2019–2024 · strength 0.90
  7. Zhefang Wang · 4 shared papers, 2019–2026 · strength 0.61
  8. Jiahui Li · 5 shared papers, 2019–2021 · strength 0.52
  9. Qiongzhu Dong · 3 shared papers, 2019–2026 · strength 0.49
  10. Thomas Schmidt · 3 shared papers, 2023–2024 · strength 0.48
  11. Philipp Lohneis · 3 shared papers, 2020–2025 · strength 0.42
  12. Utz Settmacher · 3 shared papers, 2017–2024 · strength 0.35
  13. Hans Schlößer · 3 shared papers, 2017–2025 · strength 0.34
  14. Dirk Waldschmidt · 2 shared papers, 2019–2024 · strength 0.29
  15. Julian Karlbauer · 1 shared paper, 2026 · strength 0.29
  16. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  17. Bettina Rau · 2 shared papers, 2023–2024 · strength 0.29
  18. Jiangang Zhao · 3 shared papers, 2017–2020 · strength 0.25
  19. Thomas Schmidt · 1 shared paper, 2024 · strength 0.20
  20. Steffen Ormanns · 1 shared paper, 2025 · strength 0.19
  21. Stephan Krüger · 1 shared paper, 2025 · strength 0.19
  22. Jonas M. Lehmann · 1 shared paper, 2025 · strength 0.19
  23. Jens Werner · 1 shared paper, 2025 · strength 0.19
  24. Stefan Hubert Boeck · 1 shared paper, 2025 · strength 0.19
  25. Heike Löser · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.